A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers

• Egile Nagusiak: Ruijuan Liu (Egilea), Xia Li (Egilea), Jingyao Wei (Egilea), Shuaibing Liu (Egilea), Yuanyuan Chang (Egilea), Jiali Zhang (Egilea), Ji Zhang (Egilea), Xiaojian Zhang (Egilea), Uwe Fuhr (Egilea), Max Taubert (Egilea), Xin Tian (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2019-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Despite its narrow therapeutic window and large interindividual variability, cyclosporine A (CsA) is the first-line therapy following organ transplantation. Metabolized mainly by CYP3A and being a substrate of P-glycoprotein (P-gp), CsA is susceptible to drug-drug interactions. Baicalin (BG) is a dr...